Panbela Therapeutics Share Holder Equity 2020-2024 | PBLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$153.4B
Gilead Sciences (GILD)	$121.1B
Bristol Myers Squibb (BMY)	$119.6B
Vertex Pharmaceuticals (VRTX)	$118.9B
CSL (CSLLY)	$83.5B
Regeneron Pharmaceuticals (REGN)	$74B
GSK (GSK)	$73.1B
Argenex SE (ARGX)	$39.8B
Alnylam Pharmaceuticals (ALNY)	$35B
BioNTech SE (BNTX)	$29.7B
BeiGene (ONC)	$22B
Illumina (ILMN)	$21.1B
Biogen (BIIB)	$21B
Moderna (MRNA)	$15.2B
Incyte (INCY)	$14.3B
Insmed (INSM)	$13.7B
Intra-Cellular Therapies (ITCI)	$13.5B
Genmab (GNMSF)	$13B
Genmab (GMAB)	$13B
BioMarin Pharmaceutical (BMRN)	$12.1B
Bio-Techne Corp (TECH)	$11.7B
Vaxcyte (PCVX)	$11B
Sarepta Therapeutics (SRPT)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Exact Sciences (EXAS)	$10.4B
Bio-Rad Laboratories (BIO.B)	$10B
QIAGEN (QGEN)	$9.9B
Exelixis (EXEL)	$9.5B
Repligen (RGEN)	$9.3B
Roivant Sciences (ROIV)	$8.1B